Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC55H66FN11O8S |
InChIKeyMVMNNLAXYHAMPN-VKAGSTEASA-N |
CAS Registry3055040-93-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 23 Apr 2025 | |
Neoplasms | Preclinical | United States | 23 Apr 2025 |